A clinical study of ovarian cancer initiated by investigators at the School of Medicine will combine the anti-cancer drug phenoxodiol with docetaxel for women with recurrent ovarian cancer.

"Advanced-stage ovarian cancer is one of the most devastating forms of cancer, with half of the women diagnosed with it dying within five years," says principal investigator Dr. Thomas Rutherford, associate professor in the Department of Obstetrics, Gynecology & Reproductive Sciences and a member of the Yale Cancer Center. "One of the imperatives facing doctors who treat these patients is to find ways to restore sensitivity to drugs such as taxanes once they start to lose that sensitivity."

The Phase Ib/IIa clinical study is supported by Sanofi-Aventis and Marshall Edwards Inc. It will combine phenoxodiol, which is in the investigational phase, with docetaxel, a second-generation taxane (a drug that inhibits cell growth by stopping cell division). The latter is commonly used in patients with recurrent or persistent ovarian cancer that has resisted other therapies, including the first-generation taxane paclitaxel. The clinical response rate to any chemotherapeutic is often limited due to rapid development of chemo-resistance in women with recurrent ovarian cancer.

The purpose of the study is to determine if the addition of phenoxodiol to docetaxel can improve clinical response and survival by delaying or preventing the development of chemo-resistance in women with recurrent ovarian cancer. It will include 60 women with recurrent epithelial ovarian, fallopian tube or abdominal cavity cancer after treatment with a platinum and paclitaxel. All 60 patients will be given docetaxel by injection weekly; half will also be given oral phenoxodiol daily, and the other half a placebo tablet. Treatment will continue for one year unless there is evidence of complete response, unacceptable toxicity or disease progression.

Rutherford says the rationale behind this study is based on two observations. The first is the demonstration in pre-clinical studies of the potent ability of phenoxodiol to reverse chemo-resistance in human ovarian cancer cells to docetaxel, through the ablation of anti-apoptotic proteins in the tumor cells. The second is the encouragingly high tumor response rate observed in a current clinical study where phenoxodiol is being used to chemo-sensitize paclitaxel in advanced-stage ovarian cancer patients where the tumor is taxane-resistant or refractory.

"The highly encouraging pre-clinical and clinical data that we have seen with phenoxodiol when it has been used as a chemo-sensitizer to date gives us optimism that this strategy will provide the means to improve the survival of these late-stage cancer patients," Rutherford says.

For information about participating in the study, call (203) 785-6956. Further information about the trial is also available by calling (888) 5-PHENOX or visiting www.marshalledwardsinc.com. For additional information, contact David Sheon at (202) 518-6384 or dsheon@sciwords.com.

T H I SW E E K ' SS T O R I E S

Yale and Peking University students . . . in new exchange program

Seven seniors Britain-bound as winners of Rhodes and Marshall Scholarships

Students spent Thanksgiving break helping Katrina victims

New center will foster cutting-edge neuroscience research

Grant supports study of how the aged recover

ENDOWED PROFESSORSHIPS

• Daniel Esty appointed Hillhouse Professor
  
  
• Hanming Fang named Kohn Associate Professor
  

Global terrorism is focus of talk by Major and Zedillo

Come Harvest Time at Yale's organic garden

Study finds ADHD drug reduces hyperactivity in children with PDD

Study illuminates the role of specific cells in antibody response

Clinical study tests drug combination for ovarian cancer

Symposium on nuclear physics honors . . . D. Allan Bromley

Conference honors faculty members for service to the University

Emilie Townes elected vice president of AAR

Not-So-Hidden Treasures for gift-seekers at Yale's museum shops

Holiday gifts at 'Alternative Market' help people in need

University expands its nighttime 'minibus' services

Gallery's new artist-in-residence aims to connect viewers with nature

Event to feature companies whose products are based on Yale research

David Brion Davis Lecture Series examines legacy of abolitionism

First BioHaven Entrepreneurship Seminar to take place Dec. 13

Memorial service for Boris I. Bittker

Yale Books in Brief

Campus Notes

---

Bulletin Home|Visiting on Campus|Calendar of Events|In the News

Bulletin Board|Classified Ads|Search Archives|Deadlines

Bulletin Staff|Public Affairs|News Releases| E-Mail Us|Yale Home

---